Industry News

• Trovagene announces 1 for 6 reverse stock split  Trovagene announced a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6 effective Feb. 19, 2019. The Company's common stock will begin trading on a split-adjusted basis when the markets open on Feb. 20, 2019 under the existing trading symbol "TROV."
  February 19, 2019  
• CymaBay Therapeutics announces early enrollment of a phase 2b study of seladelpar  CymaBay announced early completion of enrollment in a Phase 2b dose-ranging, paired liver biopsy study of seladelpar for treatment of nonalcoholic steatohepatitis. The company expects to report 12-week topline results on changes in liver fat and key biochemical parameters in the second quarter.
  February 19, 2019  
• GBT launches ACCEL grants program to improve access to care for people with SCD  Global Blood Therapeutics announced the launch of the Access to Excellent Care for Sickle Cell Patients Pilot Program to provide grant funding to support novel projects aimed at improving access to high-quality healthcare for sickle cell patients in the U.S.
  February 19, 2019  
• CHF Solutions enters South American market with distribution agreement in Brazil  CHF Solutions announced the initiation of a distribution agreement in the Brazilian market with Bragenix, LTDA. This agreement expands the company’s worldwide sales outreach into South America by entering the largest market in the region.
  February 19, 2019  
• Assertio Therapeutics announces FDA notification of acceptance for filing of 505(b)(2) NDA  Assertio Therapeutics announced it has received notification of acceptance for filing from the FDA for its 505(b)(2) New Drug Application for its injectable formulation of long-acting cosyntropin (synthetic adrenocorticotropic hormone, or ACTH).
  February 19, 2019  
• Bausch Health acquires Eton Pharmaceuticals' EM-100 investigational eye drops  Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, will be the first OTC preservative-free formulation eye drop for treatment of ocular itching associated with allergic conjunctivitis.
  February 19, 2019  
• Bioblast Pharma announces sale of Trehalose development programs to Seelos Therapeutics  Bioblast Pharma announced the sale of its Trehalose clinical development programs to Seelos Therapeutics. Seelos will pay Bioblast $3.5 million in two instalments; $1.5 million payable upon closing of the sale and the other $2.0 million will be paid upon the first anniversary of the sale.
  February 19, 2019  
• Aravive receives additional $2.6 million disbursement from the CPRIT of Texas  Aravive announced that the company has received an additional $2.6 million disbursement from the Cancer Prevention and Research Institute of Texas. The grant continues to support Aravive’s operations and on-going clinical development of AVB-S6-500.
  February 19, 2019  
• Intercept announces positive topline results from pivotal phase 3 REGENERATE study  Intercept Pharmaceuticals announced positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to nonalcoholic steatohepatitis. In the primary efficacy analysis, once-daily OCA 25 mg met the primary endpoint of fibrosis improvement.
  February 19, 2019  
• CRISPR Therapeutics and StrideBio expand exclusive development and option agreement  CRISPR Therapeutics and StrideBio announced that a strategic collaboration, initiated in April 2017 to generate engineered AAV capsids with improved properties for in vivo gene editing programs, has been expanded to include additional undisclosed applications. The financial terms were not disclosed.
  February 19, 2019  

   (next 10 articles)